Metraipolis › archive › dc_86a5fc65e83b

Prolonged survival in EGFR exon 20 insertion mutant lung adenocarcinoma: case report of sequential osimertinib and furmonertinib with research trend analysis — Europe PMC PMID:41585239

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41585239
DOI
10.3389/fmed.2025.1677737
License (as archived)
solo-consultazione
Archived
2026-11-06T23:07:07.527Z
SHA-256 of the archived text
5dfd645879218e6559ee3a70becdd3612fc4cd4bf4087060e02a580edafb958a
Stable URL of this page
https://metraipolis.com/documento/dc_86a5fc65e83b

How to cite

Prolonged survival in EGFR exon 20 insertion mutant lung adenocarcinoma: case report of sequential osimertinib and furmonertinib with research trend analysis — Europe PMC PMID:41585239 — Europe PMC (en), https://europepmc.org/article/MED/41585239 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_86a5fc65e83b (Metraipolis archive dc_86a5fc65e83b, sha256 5dfd645879218e6559ee3a70becdd3612fc4cd4bf4087060e02a580edafb958a)
BibTeX
@misc{dc86a5fc65e83b,
  title = {Prolonged survival in EGFR exon 20 insertion mutant lung adenocarcinoma: case report of sequential osimertinib and furmonertinib with research trend analysis — Europe PMC PMID:41585239},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41585239},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_86a5fc65e83b; sha256 5dfd645879218e6559ee3a70becdd3612fc4cd4bf4087060e02a580edafb958a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41585239. Agents can read the archived copy with the MCP tool read_document.